Parameter and Reference | Mean (SD) | Distributional Assumption |
---|---|---|
Hypothetical cohort characteristics | ||
% Positive cases [24] | 66.3% (1.4%) | Beta |
% Female | 50.0% | Not varied |
Age screened Meconium Testing | Birth | Not varied |
Age screened NST | 5 years | Not varied |
Diagnostic accuracy of screening tools | ||
Meconium testing | ||
92.4% (8.1%) | Beta | |
51.5% (19.7%) | Beta | |
The NST | ||
85.9% (5.5%) | Beta | |
72.9% (10.7%) | Beta | |
Accuracy of Diagnostic Testing | ||
Sensitivity | 100% | Not varied |
Specificity | 100% | Not varied |
Cost of screening tools and Diagnostic Testing | ||
Meconium testing [15] | $175 ($18) | Normal (bounded ±25% of mean) |
The NST b | $20 ($2) | Normal (bounded ±25% of mean) |
Cost of diagnostic testing [12] | $3870 ($387) | Normal (bounded ±25% of mean) |
Annual Cost of Healthcare Service Use | ||
First year of life [34] | $15,976 ($1598) | Log-normal |
Diagnosed FASD [34] | $3426 ($343) | Log-normal |
$2713 | Varied based on inputs a | |
Diagnosed recommended to receive psychiatric care [35] | 55.6% (7.3%) | Beta |
Undiagnosed recommended to receive psychiatric care [35] | 33.0% (14.7%) | Beta |
$3101 | Not varied | |
Future Diagnosis Rate | ||
Rate of future diagnosis for undiagnosed patients c | 5% | Uniform (bounded ±2%) |
Mortality | ||
Diagnosed FASD [6] | 3.15 (1.6) | Normal |
Increased mortality for undiagnosed | 10% | Uniform (bounded ±10%) |
FASD relative to diagnosed c | ||
No FASDc | 3.15 (2.0) | Normal |